Last reviewed · How we verify
Cosamin DS® (Nutramax)
Cosamin DS is a dietary supplement containing glucosamine and chondroitin that may help maintain cartilage structure and reduce joint inflammation in osteoarthritis.
Cosamin DS is a dietary supplement containing glucosamine and chondroitin that may help maintain cartilage structure and reduce joint inflammation in osteoarthritis. Used for Osteoarthritis pain and joint function support.
At a glance
| Generic name | Cosamin DS® (Nutramax) |
|---|---|
| Also known as | Cosamin DS®, glucosamine hydrochloride and chondroitin sulphate |
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Dietary supplement / nutraceutical |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Orthopedics |
| Phase | Phase 3 |
Mechanism of action
Glucosamine is thought to provide building blocks for cartilage repair and may stimulate cartilage-producing cells (chondrocytes), while chondroitin may help retain water in cartilage and inhibit cartilage-degrading enzymes. Together, these components are proposed to slow cartilage breakdown and support joint function in degenerative joint disease.
Approved indications
- Osteoarthritis pain and joint function support
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Allergic reactions (rare, shellfish-derived glucosamine)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cosamin DS® (Nutramax) CI brief — competitive landscape report
- Cosamin DS® (Nutramax) updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI